Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial.
Pellegrino B, Capoluongo ED, Bagnoli M, Arenare L, Califano D, Scambia G, Cecere SC, Silini EM, Scaglione GL, Spina A, Tognon G, Campanini N, Pisano C, Russo D, Pettinato A, Scollo P, Iemmolo R, De Cecco L, Musolino A, Marchini S, Beltrame L, Paracchini L, Perrone F, Mezzanzanica D, Pignata S. Pellegrino B, et al. Among authors: pisano c. ESMO Open. 2025 Jan 3;10(1):104091. doi: 10.1016/j.esmoop.2024.104091. Online ahead of print. ESMO Open. 2025. PMID: 39754985 Free article.
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.
Fabbi M, Costa D, Russo D, Arenare L, Gaggero G, Signoriello S, Scambia G, Pisano C, Colombo N, Losito NS, Filaci G, Spina A, Califano D, Scognamiglio G, Gadducci A, Mezzanzanica D, Bagnoli M, Ferrini S, Canzonieri V, Chiodini P, Perrone F, Pignata S. Fabbi M, et al. Among authors: pisano c. Diagnostics (Basel). 2022 Aug 31;12(9):2118. doi: 10.3390/diagnostics12092118. Diagnostics (Basel). 2022. PMID: 36140519 Free PMC article.
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
Pignata S, Califano D, Lorusso D, Arenare L, Bartoletti M, De Giorgi U, Andreetta C, Pisano C, Scambia G, Lombardi D, Farolfi A, Cinieri S, Passarelli A, Salutari V, De Angelis C, Mignogna C, Priolo D, Capoluongo ED, Tamberi S, Scaglione GL, Arcangeli V, De Cecio R, Scognamiglio G, Greco F, Spina A, Turinetto M, Russo D, Carbone V, Casartelli C, Schettino C, Perrone F. Pignata S, et al. Among authors: pisano c. Ann Oncol. 2024 Jul;35(7):667-676. doi: 10.1016/j.annonc.2024.04.007. Epub 2024 May 3. Ann Oncol. 2024. PMID: 38704093 Clinical Trial.
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
Roma C, Esposito Abate R, Sacco A, Califano D, Arenare L, Bergantino F, Pisano C, Cecere SC, Scambia G, Lorusso D, Artioli G, Tasca G, Spina A, Russo D, Gadducci A, De Angelis C, Bologna A, Marchini S, Capoluongo ED, Perrone F, Pignata S, Normanno N. Roma C, et al. Among authors: pisano c. Eur J Cancer. 2024 Jul;206:114127. doi: 10.1016/j.ejca.2024.114127. Epub 2024 May 23. Eur J Cancer. 2024. PMID: 38797038
Treatment of recurrent epithelial ovarian cancer.
Pignata S, Pisano C, Di Napoli M, Cecere SC, Tambaro R, Attademo L. Pignata S, et al. Among authors: pisano c. Cancer. 2019 Dec 15;125 Suppl 24:4609-4615. doi: 10.1002/cncr.32500. Cancer. 2019. PMID: 31967680 Free article. Review.
Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy.
Ventriglia J, Paciolla I, Pisano C, Tambaro R, Cecere SC, Di Napoli M, Attademo L, Arenare L, Spina A, Russo D, Califano D, Losito NS, Setola SV, Franzese E, De Vita F, Orditura M, Pignata S. Ventriglia J, et al. Among authors: pisano c. Int J Gynecol Cancer. 2021 Jan;31(1):110-113. doi: 10.1136/ijgc-2020-001540. Epub 2020 Aug 12. Int J Gynecol Cancer. 2021. PMID: 32796087
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Daniele G, Raspagliesi F, Scambia G, Pisano C, Colombo N, Frezzini S, Tognon G, Artioli G, Gadducci A, Lauria R, Ferrero A, Cinieri S, De Censi A, Breda E, Scollo P, De Giorgi U, Lissoni AA, Katsaros D, Lorusso D, Salutari V, Cecere SC, Zaccarelli E, Nardin M, Bogani G, Distefano M, Greggi S, Piccirillo MC, Fossati R, Giannone G, Arenare L, Gallo C, Perrone F, Pignata S. Daniele G, et al. Among authors: pisano c. Int J Gynecol Cancer. 2021 Jun;31(6):875-882. doi: 10.1136/ijgc-2021-002434. Epub 2021 Apr 30. Int J Gynecol Cancer. 2021. PMID: 33931498 Clinical Trial.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Di Liello R, Arenare L, Raspagliesi F, Scambia G, Pisano C, Colombo N, Frezzini S, Tognon G, Artioli G, Gadducci A, Lauria R, Ferrero A, Cinieri S, De Censi A, Breda E, Scollo P, De Giorgi U, Lissoni AA, Katsaros D, Lorusso D, Salutari V, Cecere SC, Lapresa M, Nardin M, Bogani G, Distefano M, Greggi S, Gargiulo P, Schettino C, Gallo C, Daniele G, Califano D, Perrone F, Pignata S, Piccirillo MC. Di Liello R, et al. Among authors: pisano c. Int J Gynecol Cancer. 2021 Oct;31(10):1348-1355. doi: 10.1136/ijgc-2021-002786. Epub 2021 Aug 30. Int J Gynecol Cancer. 2021. PMID: 34462317 Clinical Trial.
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.
D'Alterio C, Spina A, Arenare L, Chiodini P, Napolitano M, Galdiero F, Portella L, Simeon V, Signoriello S, Raspagliesi F, Lorusso D, Pisano C, Colombo N, Zannoni GF, Losito NS, De Cecio R, Scognamiglio G, Califano D, Russo D, Tuninetti V, Piccirillo MC, Gargiulo P, Perrone F, Pignata S, Scala S. D'Alterio C, et al. Among authors: pisano c. Cancers (Basel). 2022 Apr 6;14(7):1849. doi: 10.3390/cancers14071849. Cancers (Basel). 2022. PMID: 35406620 Free PMC article.
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Musacchio L, Califano D, Bartoletti M, Arenare L, Lorusso D, Losito NS, Cormio G, Greggi S, Raspagliesi F, Valabrega G, Salutari V, Pisano C, Spina A, Russo D, Del Sesto M, Canzonieri V, Ferraù F, Zannoni GF, Loizzi V, Ghizzoni V, Casanova C, Tuninetti V, Ducceschi M, Del Vecchio V, Scalone S, Priolo D, Perrone F, Scambia G, Pignata S. Musacchio L, et al. Among authors: pisano c. Br J Cancer. 2022 Nov;127(8):1479-1486. doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22. Br J Cancer. 2022. PMID: 35869143 Free PMC article.
420 results